AtCor Medical (ASX: ACG), the developer and marketer of the SphygmoCor® system which measures central blood pressure and arterial stiffness noninvasively, announced that it would debut SphygmoCor Version 9 at the Annual American College of Cardiology Scientific Session Exposition being held in Atlanta, March 14-16, 2010.

Inovio Biomedical Corporation, a leader in DNA vaccine design, development and delivery, has unveiled its new CELLECTRA®-SP series of hand-held, cordless electroporation devices at the DNA Vaccines 2010 conference being held in New Orleans, LA.

Sequella, Inc., a clinical-stage biopharmaceutical company focused on commercializing novel antibiotics to treat life-threatening infectious diseases, today announced that it received a $594,661 two-year Small Business Innovative Research (SBIR) grant from the National Institutes of Health (NIH), National Institute of Allergy and Infectious Diseases (NIAID) for the development of SQ641, Sequella's lead compound in its capuramycin series, a new class of antibiotic.